Please wait a minute...
ZJUS-B
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2012, Vol. 13 Issue (1): 56-82    DOI: 10.1631/jzus.B1100120
Review     
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy
Jing Tong, You-wei Wang, Yuan-an Lu
Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii 96822, USA, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Institute of Traditional Chinese Medicine & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.

Key words： Hepatitis C virus (HCV)      Clinical trial      Small molecular compounds      Review     
Received: 25 March 2011      Published: 30 December 2011
CLC:  R575.1  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Jing Tong
You-wei Wang
Yuan-an Lu
Cite this article:

Jing Tong, You-wei Wang, Yuan-an Lu. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2012, 13(1): 56-82.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B1100120     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2012/V13/I1/56

[1] Lie-dao Yu, Zhi-yun Feng, Xuan-wei Wang, Zhi-heng Ling, Xiang-jin Lin. Fungal spondylodiscitis in a patient recovered from H7N9 virus infection: a case study and a literature review of the differences between Candida and Aspergillus spondylodiscitis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2016, 17(11): 874-881.
[2] Yong-song GUAN, Yuan LIU, Qing ZOU, Qing HE, Zi LA, Lin YANG, Ying HU. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(5): 331-340.